(Copenhagen, December 21, 2021). ZERION Pharma A/S, a Danish pharmaceutical company, elected Dr. Dorte Arnbjerg to join its board of directors at an extraordinary general meeting held on December 14, 2021.
Dr. Dorte Arnbjerg (born 1961), is educated as a dentist and holds a Ph.D. degree from the University of Aarhus, and a Master’s degree in Public Health from Johns Hopkins University. Dr. Arnbjerg is an experienced leader & drug developer and joins ZERION’s board with more than 20 years of experience from the pharmaceutical industry. Dr. Arnbjerg has a strong background in international drug development within CMC & clinical development of early and late-stage development programs including successful regulatory drug approvals. Dorte has R&D leadership experience from biotech- & small to large-sized pharmaceutical companies. She is Senior Vice President at H. Lundbeck A/S.
“With her solid experience from manufacturing and clinical development, Dorte Arnbjerg is bringing very important expertise to ZERION, and we are excited to welcome her as a new board member. The election of Dorte is an important step forward to professionalize all parts of our company and I am convinced that in addition to the more operational qualifications she brings in, Dorte will be an important contributor to define and execute on the future strategic direction for ZERION", says Ole Wiborg, CEO of ZERION Pharma.
Earlier in May 2021, ZERION elected Dr. Torsten Goesch and Dr. Lars Lykke Thomsen to the board of directors. With the addition of Dr. Arnbjerg to the board, ZERION is well-positioned to continue its mission to commercialise the Dispersome® technology and bring new and better performing drugs to the patients.
ZERION is a pharmaceutical development company specialising in improving the bioavailability of oral drug products by increasing their solubility. The company has pioneered the patented Dispersome® formulation technology that enables poorly soluble drugs to reach their true therapeutic potential. Poor drug solubility is one of the biggest challenges hampering the commercial development of novel small molecule drugs. Approximately 90% of all oral drugs in pharmaceutical pipelines do not sufficiently dissolve in the digestive tract and therefore cannot be absorbed into the circulation to exert their therapeutic effect. Many otherwise promising drug candidates are thus discontinued during early-stage development due to poor bioavailability.
ZERION has pioneered the Dispersome® platform technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and the therapeutic options for patients. The Dispersome® technology is based on preparing stable amorphous formulations by mixing high loads of the drug compound with beta-lactoglobulin, which is produced from a sustainable source of whey protein, a by-product from cheese production. ZERION develops proprietary drug formulations and offers the Dispersome® technology to established pharma companies as a means to solve their most challenging drug solubility problems. The Dispersome® technology is patent protected and offers in connection with any pharmaceutical drug many additional years of IP protection.
In addition to its internal product portfolio, ZERION is collaborating with several established pharmaceutical companies.
For more information contact Ole Wiborg, CEO at +45 40 96 80 18
AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop
AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field.
February 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) announces today that it has executed a long-term agreement with Arla Foods Ingredients covering the supply of its Lacprodan® BLG-100 for use as